MULTIVARIANT META-ANALYSIS OF KRAS MUTATIONS'S PREDICTIVE VALUE FOR RESPONSE TO CETUXIMAB IN COLORECTAL CANCER

被引：0
作者：
Tsoukalas, N. [1 ,2 ]
Bagos, P. [2 ]
Hamodrakas, S. [2 ]
机构：
[1] 401 Gen Army Hosp, Athens, Greece
[2] Univ Athens, Fac Biol, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [21] Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis
    Zhang, Linlin
    Ma, Li
    Zhou, Qinghua
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (08) : 1025 - 1033
  • [22] Development of an assay for KRAS mutation as a predictive marker for cetuximab in colorectal cancer
    Yokota, T.
    Muro, K.
    Shibata, N.
    Ura, T.
    Takahari, D.
    Shitara, K.
    Yatabe, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer
    Di Fiore, F.
    Le Pessot, F.
    Lamy, A.
    Charbonnier, F.
    Sabourin, J.
    Paillot, B.
    Frebourg, T.
    Michel, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
    Lee, Jeeyun
    Lee, Inkyoung
    Han, Boram
    Park, Joon Oh
    Jang, Jiryeon
    Park, Chaehwa
    Kang, Won Ki
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08): : 674 - 688
  • [25] Predictive value of FcγRIIa/FcγRIIIa receptors and KRAS mutations in metastatic colorectal cancers treated by cetuximab and irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Ychou, M.
    Lamy, A.
    Blanchard, F.
    Frebourg, T.
    Michel, P.
    Sabourin, J. C.
    Boissiere-Michot, P.
    BULLETIN DU CANCER, 2008, 95 : S48 - S49
  • [26] The prognostic value of KRAS mutations in patients with colorectal cancer
    Inoue, Yasuhiro
    Saigusa, Susumu
    Iwata, Takashi
    Okugawa, Yoshinaga
    Toiyama, Yuji
    Tanaka, Koji
    Uchida, Keiichi
    Mohri, Yasuhiko
    Kusunoki, Masato
    ONCOLOGY REPORTS, 2012, 28 (05) : 1579 - 1584
  • [27] Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
    Koulouridi, Asimina
    Karagianni, Michaela
    Messaritakis, Ippokratis
    Sfakianaki, Maria
    Voutsina, Alexandra
    Trypaki, Maria
    Bachlitzanaki, Maria
    Koustas, Evangelos
    Karamouzis, Michalis, V
    Ntavatzikos, Anastasios
    Koumarianou, Anna
    Androulakis, Nikolaos
    Mavroudis, Dimitrios
    Tzardi, Maria
    Souglakos, John
    CANCERS, 2022, 14 (14)
  • [28] Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
    Han, Cheng-Bo
    Li, Fan
    Ma, Jie-Tao
    Zou, Hua-Wei
    CANCER INVESTIGATION, 2012, 30 (10) : 741 - 747
  • [29] Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases
    Brudvik, K. W.
    Kopetz, S. E.
    Li, L.
    Conrad, C.
    Aloia, T. A.
    Vauthey, J. -N.
    BRITISH JOURNAL OF SURGERY, 2015, 102 (10) : 1175 - 1183
  • [30] A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Liu, Tong
    Jiang, Shuai
    Teng, Xue
    Zhong, Lu
    Liu, Mengmeng
    Jin, Yao
    Dong, Mei
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2023, 45 (01) : 1 - 9
12345